New Poll of Midterm Voters Shows Overwhelming, Bipartisan Support for Passage of the ASAP Act (H.R.6130 / S.3267) This Year
With strong public support and significant momentum, Congress has an opportunity to ensure Medicare policy keeps pace with rapidly advancing Alzheimer’s science
WASHINGTON, D.C. – A new poll of 2026 midterm voters reveals overwhelming, bipartisan support for passing the Alzheimer’s Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), legislation that would expand access to innovative tools for earlier Alzheimer’s detection. The findings also underscore strong public support for making Alzheimer’s disease a national priority and demonstrate that voters want Congress to act during the lame duck session.
Lake Research Partners and The Tarrance Group surveyed 1,196 registered voters who cast ballots in the 2026 elections and found strong support for Alzheimer’s legislative solutions:
Nearly nine in ten voters (89%) support the Alzheimer’s Screening and Prevention (ASAP) Act, with 76% strongly supporting the legislation.
Support for the ASAP Act is broad across the political spectrum, with 95% of Democrats, 87% of independents, and 83% of Republicans expressing support.
70% say it is important for Congress to prioritize passing the ASAP Act during the lame-duck session, including nearly 36% who say it is very important.
This urgency is shared across party lines. Majorities of Democrats (79%), independents (68%), and Republicans (62%) say passing the legislation this year should be a priority. Notably, nearly half of Democrats (44%) and independents (47%) say it is very important for Congress to act before the end of the year.
More than three-quarters of voters (77%) say fighting Alzheimer’s should be a national priority.
“These findings reinforce that addressing Alzheimer’s disease is not a partisan issue. Voters across the political spectrum recognize the devastating impact this disease has on millions of American families and want to see meaningful action,” said Ken Thorpe, Honorary Chair of PFCD. “Congress has already demonstrated important leadership in advancing solutions to improve Alzheimer’s detection and care. Now is the time to build on that momentum and get the ASAP Act across the finish line.”
As scientific innovation continues to expand opportunities for earlier identification of Alzheimer's disease, it is critical that policies keep pace to ensure timely patient access to breakthrough tools. The ASAP Act would establish a pathway for Medicare coverage of FDA-cleared blood tests for early Alzheimer’s screening through an evidence-based process.
The legislation has already garnered significant momentum on Capitol Hill and across the patient advocacy community. The ASAP Act has secured over 235 cosponsors in the House and nearly 60 cosponsors in the Senate, reflecting broad, bipartisan support in both chambers. The House Ways and Means Committee also advanced the legislation unanimously in a 40-0 vote. PFCD joined more than 525 organizations in signing a coalition letter, spearheaded by the Alzheimer’s Impact Movement (AIM) and the LEAD Coalition, urging Congress to advance the legislation. With strong bipartisan support from lawmakers, patient advocates, and the public alike, Congress has an opportunity to translate this momentum into meaningful progress for the millions of Americans impacted by Alzheimer’s disease.
“Voters have spoken,” said Thorpe. “Across the political spectrum they support early detection, are eager for national action on Alzheimer's, and urge Congress to deliver. The call is bipartisan, broad, and unambiguous. The window to act is now.”
Results of the poll can be found HERE.
###